Accepted Cohorts: No cohorts were accepted in this release.
New Cohorts: 13 were added.
348: [P] Hematuria (7Pe, 30Era)
349: [P] Lower gastrointestinal bleeding events (7Pe, 30Era)
350: [P] Hemoptysis (7Pe, 30Era)
351: [P] Nasal Polyp (365Pe, 365Era)
352: [P] Inflamed Tonsil (7Pe, 30Era)
353: [P] Conjunctivitis (3Pe, 7Era)
354: [P] Nasal Congestion or Rhinitis or Common Cold (3Pe, 7Era)
355: [P] Laryngitis (3Pe, 7Era)
356: [P] Epistaxis (3Pe, 7Era)
357: [P] Pulmonary Edema (3Pe, 30Era)
358: [P] Acute Respiratory Failure among persons with no chronic respiratory failure (3Pe, 30Era)
359: [P] Acute Respiratory Failure (3Pe, 30Era)
360: [P] Pleural Effusion (3Pe, 30Era)
Accepted Cohorts: 2 were accepted. 234: Appendicitis (1Pe, 180Era) 213: Acquired Neutropenia or unspecified leukopenia (21Pe, 365Era)
New Cohorts: 9 were added.
339: [P] Hypotension (1Pe, 3Era)
340: [P] Hives, Erythema, Eruption, Urticaria (1Pe, 7Era)
341: [P] Loss of mentation including coma, loss of consciousness, altered consciousness (1Pe, 3Era)
342: [P] Urinary Incontinence (1Pe, 3Era)
343: [P] Fecal Incontinence (1Pe, 3Era)
344: [P] Doctors office or clinic visit without other overlapping visits (0Pe, 0Era)
345: [P] Doctors office or clinic visit (0Pe, 0Era)
346: [P] Non urgent outpatient visit without overlapping inpatient or emergency visit (0Pe, 0Era)
347: [P] Ambulance utilization (0Pe, 0Era)
Accepted Cohorts: The following cohorts were added
119: Systemic lupus erythematosus indexed on signs, symptoms, treatment or diagnosis (FP)
296: Transverse myelitis or symptoms indexed on symptoms or diagnosis (180Pe, 180Era)
New Cohorts: 17 were added.
142: [P] Earliest event of ST elevated myocardial infarction (7P, 1E)
192: [P] Skin or mucosal bleeding events (1Pe, 7Era)
298: [P] Urinary bleed events in persons without renal glomerular disease (30Pe, 7Era)
299: [P] Acute gastrointestinal bleeding events (7Pe, 30Era)
300: [P] Heavy menstrual bleeding (menorrhagia) events (60Pe, 180Era)
318: [P] All events of Acute Hepatic Failure in persons without chronic hepatic failure (90Pe, 365Era)
324: [P] Pain (3Pe, 7Era)
325: [P] Inpatient Hospitalization By Site of care or type of service (0Pe, 1Era)
327: [P] Pharyngitis (3Pe, 7Era)
328: [P] Wheezing (3Pe, 30Era)
329: [P] Pneumonitis and lung infections (14Pe, 30Era)
330: [P] Abdominal Bloating (1Pe, 7Era)
331: [P] Encephalopathy (1Pe, 14Era)
332: [P] Pain or ache that is Chronic (3Pe, 180Era)
333: [P] Alcohol Use Disorder (365Pe, 365Era)
334: [P] Asthma (FP)
335: [P] Anxiety or Fear (3Pe, 30Era)
Deprecated Cohorts: No new cohorts were added in this release.
New Cohorts: 19 were added.
134: [P] Persons with Attention Deficit Hyperactivity Disorder (FP)
278: [P] Pain that is Non Chronic, Non Generalized (3Pe, 7Era)
279: [P] Low Back Pain (30Pe, 180Era)
280: [P] Abdominal Pain (3Pe, 7Era)
281: [P] Epigastric Pain (3Pe, 7Era)
282: [P] Joint Pain (3Pe, 30Era)
283: [P] Prostatitis (180Pe, 365Era)
284: [P] Myocarditis or Pericarditis (30Pe, 90Era)
285: [P] Myocarditis or Pericarditis Not due to infections (30Pe, 90Era)
287: [P] Transverse myelitis includes Myelitis Unspecified and neuromyelitis optica (90Pe, 365Era)
288: [P] Type 2 Diabetes Mellitus indexed on diagnosis, treatment or lab results (FP)
289: [P] Presence Of Cardiac Arrhythmia (3Pe, 60Era)
290: [P] Thyroiditis indexed on diagnosis or treatment without (FP)
291: [P] Gynecomastia, indexed on diagnosis, procedure or symptoms (FP)
292: [P] Hepatic Failure (365Pe, 365Era)
293: [P] Acute Hepatic Injury with no chronic hepatic failure (180Pe, 180Era)
294: [P] Acute Hepatic Injury with no pre-existing liver disease (180Pe, 180Era)
295: [P] Acute Hepatic Failure in persons with no pre-existing liver disease (365Pe, 365Era)
296: Transverse myelitis or symptoms indexed on symptoms or diagnosis (180Pe, 180Era)
Deprecated Cohorts: No new cohorts were added in this release.
Accepted Cohorts: The following cohorts were added
269: Acute Kidney Injury AKI (7Pe, 30W)
Discussed https://forums.ohdsi.org/t/phenotype-phebruary-day-29-acute-kidney-injury/16067 and peer reviewed by Azza Shoaibi and accepted after modifications. See recording dated August 12th 2022
New Cohorts: 2 were added.
276: [P] Sudden Vision Loss (1Pe, 0Era, 365W)
277: [P] Sudden Hearing Loss (1Pe, 0Era, 365W)
Deprecated Cohorts: No new cohorts were added in this release.
Accepted Cohorts: The following cohorts were added
63: Transverse myelitis or symptoms (1Ps, 0Era, 365W)
Deprecated Cohorts: No new cohorts were added in this release.
Modified Cohorts: several symptom and sign based cohorts were updated to support discussion https://forums.ohdsi.org/t/phenotype-submission-symptoms-and-signs/17895
New Cohorts: 2 were added.
270: [P] Hemolytic Anemia (7Pe, 0Era, 365W)
271: [P] Hemolytic Anemia Intra corpuscular (FP)
Deprecated Cohorts: No new cohorts were added in this release.
Modified Cohorts: 0 were modified.
New Cohorts: 11 were added.
258: [P] Anaphylaxis or Anaphylactic shock events (1Pe, 0Era, 30W)
259: [P] Anaphylaxis all cause (1Pe, 0Era, 30W)
260: [P] ST elevated myocardial infarction with inpatient admission (7Pe, 180Era)
261: [P] Non ST elevated myocardial infarction with inpatient admission (7Pe, 180Era)
262: [P] Unstable Angina with inpatient admission (7Pe, 180Era)
263: [P] Unstable Angina OR NSTEMI with inpatient admission (7Pe, 180Era)
264: [P] Acute Hepatic Failure in persons with liver disease (90Pe, 180W)
265: [P] Drug Induced Acute Hepatic Failure (90Pe, 180W)
267: [P] Acute Kidney Injury AKI, in persons with chronic kidney disease (7Pe, 30W)
268: [P] Acute Kidney Injury AKI, in persons with NO chronic kidney disease (7Pe, 30W)
269: [P] Acute Kidney Injury (AKI) (7Pe, 30W)
Deprecated Cohorts: No new cohorts were added in this release.
Modified Cohorts: 3 were modified.
71: [P] Acute myocardial infarction with inpatient admission (7Pe, 180Era)
221: [P] Anaphylaxis Non Environmental exposure related (1Pe, 0Era, 30W)
234: [P] Appendicitis (1Pe, 0Era, 365W)
Accepted Cohort: 3 cohorts were accepted. cohortId 23, 24 and 25 were considered accepted to the OHDSI Phenotype Library. This cohort is deemed validated as it represents a convention and thus do not need to go through peer review process.
23: Inpatient Hospitalization (1Pe, 0Era)
24: Emergency room visits (0Pe, 0Era)
25: All cause mortality
New Cohorts: 8 were added.
100: [P] Alzheimer's disease
119: [P] Systemic lupus erythematosus (FP)
251: [P] Acute pancreatitis (7Pe, 0Era, 365W)
253: [P] Drug Induced Acute pancreatitis (7Pe, 365W)
254: [P] Drug Resistant Epilepsy
255: [P] Alzheimer's disease (based on Imfeld, 2013)
256: [P] Facial Palsy lower motor neuron including Bells Palsy (180Pe, 0Era, 183W)
257: [P] Emergency room visits or code (0Pe, 0Era)
Deprecated Cohorts: No cohorts were added in this release.
Modified Cohorts: 136 were modified. Several cohorts were changed from [P] to [W] i.e. were withdrawn from peer review consideration. Some of the cohorts in [P] pending peer review status were modified by the contributor. The changes includes cohort name changes and cohort specification changes. No accepted cohorts were modified.
2: [W] COVID-19 diagnosis or SARS-CoV-2 test (1pos) (3Ps, 7Era)
3: [P] Cough (3Ps, 30Era)
4: [P] Diarrhea (7Ps, 30Era)
5: [P] Dyspnea (14Pe, 30Era)
6: [P] Fever (3Pe, 30Era)
7: [P] Headache, Migraine or related Neurologic pain (7Pe, 30Era)
8: [P] Anosmia OR Hyposmia OR Dysgeusia (7Ps, 180Era)
9: [P] Sore throat (7Pe, 30Era)
10: [P] Nausea or Vomiting (3Pe, 30Era)
11: [P] Malaise or fatigue (3P, 30Era)
12: [P] Rhinitis or common cold (7P, 30Era)
13: [P] Myalgia (not explained by injury, ischemia or systemic inflammation) (3Pe, 30Era)
14: [P] Myalgia (3Pe, 30Era)
15: [W] Exposure to Viral Disease (7Pe, 30Era)
16: [W] Exposure to SARS-Cov 2 and coronavirus (7Pe, 30Era)
17: [W] Exposure to SARS-Cov 2 (7Pe, 30Era)
18: [P] Multiple Inflammatory Syndrome (30Pe, 30Era)
19: [P] Acute Typical Pneumonia (14Pe, 30Era)
20: [P] Bronchitis (14Pe, 90Era)
21: [P] Acute respiratory distress syndrome (ARDS) or Acute Respiratory Failure (3Pe, 30Era)
22: [W] SARS-CoV-2 testing (1Ps, 0Era)
26: [P] Asthma or Chronic obstructive pulmonary disease (COPD) (FP)
27: [P] Asthma without COPD (FP)
28: [P] Chronic obstructive pulmonary disease (COPD) without asthma (FP)
29: [W] Autoimmune condition (FP)
30: [P] Tuberculosis (FP)
31: [P] Malignant neoplasm excluding non-melanoma skin cancer (FP)
32: [P] Obesity (FP)
33: [P] Dementia (FP)
34: [P] Hypertensive disorder or hypertensive complications (FP)
35: [W] Chronic kidney disease (FP)
36: [P] Human immunodeficiency virus (not HIV2) infection (FP)
37: [P] Hepatitis C (FP)
38: [P] Heart disease (FP)
39: [W] End stage renal disease (FP)
40: [P] Diabetes Mellitus Type 2 (FP)
41: [W] Chronic kidney disease broad (FP)
42: [W] End stage renal disease broad (FP)
43: [P] Respiratory or pulmonary tuberculosis (FP)
44: [W] COVID-19 diagnosis (3Pe, 7Era)
45: [W] COVID-19 diagnosis with SARS-Cov-2 test (-3d to 3d) (3Pe, 21Era)
46: [W] COVID-19 diagnosis and SARS-CoV-2 test (1pos) within 3d (3Pe, 21Era)
47: [W] COVID-19 diagnosis and SARS-CoV-2 test (1pos) (0neg) within 3d (3Pe, 21Era)
48: [W] COVID-19 diagnosis and SARS-CoV-2 test (0pos upto 3d, 1neg within 3d) (3Pe, 7Era)
51: [W] SARS-CoV-2 test positive result (0Ps, 0Era)
52: [W] SARS-CoV-2 test negative result (0Ps, 0Era)
53: [W] SARS-CoV-2 test positive or negative result - keep persons with positive (0Ps, 0Era)
54: [P] Febrile seizure (1Pe, 0Era, 42W)
55: [W] COVID-19 diagnosis or SARS-CoV-2 test (1pos) (3Ps, 21Era)
56: [P] SARS-CoV-2 test (1pos) or COVID-19 diagnosis with (0 neg -3d to 3d) (3Ps, 21Era)
57: [P] Bleeding (1Pe, 0Era, 30W)
58: [W] SARS-CoV-2 test positive result (3Ps, 21Era)
59: [W] COVID-19 diagnosis with no SARS-CoV-2 test (3Ps, 21Era)
60: [W] SARS-CoV-2 test positive and negative result (0Ps, 0Era)
61: [P] Bradycardia or heart block with inpatient admission (1Pe, 30Era)
62: [P] Generalized Seizure (1Pe, 0Era, 42W)
63: [P] Transverse myelitis or symptoms (1Ps, 0Era, 365W)
64: [W] Flu-like symptoms fever, cough, malaise, fatigue, dyspnea, myalgia (3P, 30Era)
65: [W] Acute pancreatitis with inpatient admission (3Pe, 30Era)
66: [W] Acute renal failure with inpatient admission (3Pe, 30Era)
67: [W] Hepatic failure with inpatient admission (3Pe, 30Era)
68: [W] Heart failure with inpatient admission (3Pe, 30Era)
69: [W] Angioedema with inpatient admission (7Ps, 30Era)
70: [P] Stroke (ischemic or hemorrhagic) with inpatient admission (7Ps, 30Era)
71: [P] Acute myocardial infarction with inpatient admission (7Ps, 180Era)
72: [P] Influenza diagnosis or positive test result (7Pe, 90Era)
73: [W] Pregnancy (270P, 0Era)
74: [P] Hemorrhagic stroke (intracerebral bleeding) with inpatient admission (7Ps, 180Era)
75: [P] Ischemic stroke with inpatient admission (7Ps, 180Era)
76: [P] Transient ischemic attack with inpatient admission (7Ps, 30Era)
77: [P] Gastrointestinal bleeding with inpatient admission (7Ps, 30Era)
78: [P] Cardiac arrhythmia with inpatient admission (1Pe, 30Era)
79: [P] Dialysis with inpatient admission (1Ps, 7Era)
80: [P] Extracorporeal Membrane Oxygenation with inpatient admission (1Pe, 30Era)
81: [P] Cesarean section (7Pe, 180Era)
82: [P] Intensive services during hospitalization (1Ps, 30Era)
84: [P] SARS-CoV-2 test (1pos) or COVID-19 diagnosis with (1pos or 0 neg 0d to 3d) (3Ps, 180Era)
85: [P] SARS-CoV-2 test (1pos) or COVID-19 diagnosis with (1pos or 0 neg 0d to 3d) (3Ps, 21Era)
86: [W] SARS-CoV-2 test positive or negative result (0Ps, 0Era)
87: [W] SARS-CoV-2 test (1Ps, 0Era)
95: [P] Delirium (FP)
123: [W] First event of Suicide attempt, including injuries and poisonings with undetermined, 365 days
189: [P] Right Upper Quadrant Pain (Pe1, 0Era, 14W)
190: [P] Abdominal Distension (Pe1, 0Era, 14W)
191: [P] Fatigue, Malaise, Lethargy, Anorexia (Pe1, 0Era, 14W)
192: [P] Nausea or Vomiting (Pe1, 0Era, 7W)
193: [P] Jaundice or Itching (Pe1, 0Era, 14W)
194: [P] Encephalopathy or its presentations (Pe1, 0Era, 30W)
195: [P] Urothelial bladder cancer (FP)
197: [P] Coronary Artery Disease from vessel disease to ischemic injury (FP)
205: [W] Acute pancreatitis (7Pe, 0Era, 365W)
206: [W] Drug Induced Acute pancreatitis (7Pe, 365W)
207: [P] Acquired Pure Red Cell Aplasia
208: [P] Neutropenic Fever (3Pe, 30Era)
209: [P] Hemolytic Anemia, Extra corpuscular Acquired - G6PD deficiency excluded (7Pe, 0Era, 365W)
210: [P] Hemolytic Anemia, Extra corpuscular Acquired (7Pe, 0Era, 365W)
211: [P] Pancytopenia, Acquired
213: [P] Acquired Neutropenia or unspecified leukopenia (21Pe, 365Era)
214: [P] Acquired Isolated Neutropenia or unspecified leukopenia (21Pe, 365Era)
215: [P] Isolated Immune Thrombocytopenia (180Pe, 365Era)
216: [P] Isolated Immune Thrombocytopenia in absence of common thrombocytopenia causes (180Pe, 365Era)
217: [P] Thrombotic microangiopathy (TMA) or Microangiopathic hemolytic anemia (MAHA)
218: [P] Rhabdomyolysis (3Pe, 0Era, 180W)
219: [P] Sudden Cardiac arrest or cardiac death
220: [P] Angioedema (3Pe, 0Era, 180W)
221: [P] Anaphylaxis Non Environmental exposure related (1Pe, 0Era, 180W)
222: [P] Stevens-Johnson syndrome, toxic epidermal necrolysis spectrum
223: [P] Posterior reversible encephalopathy syndrome PRES (FP)
224: [P] Long QT Syndrome or QT prolonged (Acquired)
225: [P] Drug-induced Lupus (180Pe, 0Era, 365W)
226: [P] Drug Rash with Eosinophilia and Systemic Symptoms DRESS (1Pe, 0Era, 365W)
227: [P] Severe Cutaneous Adverse Reaction SCAR (SJS+TEN+DRESS+EM) (3Pe, 0Era, 365W)
228: [P] Severe Cutaneous Adverse Reaction SCAR (SJS+TEN+DRESS) (3Pe, 0Era, 365W)
229: [P] Progressive multifocal leukoencephalopathy
230: [P] Autoimmune hepatitis (1Pe, 0Era, 365W)
231: [P] Erythema multiforme (3Pe, 0Era, 365W)
232: [P] Paresthesia (3Pe, 0Era, 365W)
233: [P] Hemorrhagic stroke (1Pe, 0Era, 180W)
234: [P] Appendicitis (1Pe, 0Era, 365W)
235: [P] Guillain Barre syndrome (180Pe, FP)
236: [P] Idiopathic Peripheral Neuropathy (1Pe, 0Era, 365W)
237: [P] Kawasaki disease (1Pe, 0Era, 365W)
238: [P] Optic Neuritis (7Pe, 0Era, 365W)
239: [P] Narcolepsy events (1Pe, 0Era, 365W)
240: [P] Muscle weakness or monoplegia (1Pe, 0Era, 365W)
241: [P] Urticaria (1Pe, 0Era, 30W)
243: [P] Tinnitus (1Pe, 0Era, 365W)
244: [P] Dizziness (1Pe, 0Era, 180W)
245: [P] Hepatic Thrombosis (90Pe, 0Era)
246: [P] Portal vein thrombosis (90Pe, 0Era)
247: [P] Deep Vein Thrombosis DVT (90Pe, 0Era)
248: [P] Disseminated intravascular coagulation DIC (1Pe, 0Era, 365W)
249: [P] Ischemic (Non-hemorrhagic) Stroke (1Pe, 0Era, 365W)
New Cohorts: 43 were added. 205: [P] Acute pancreatitis (7Pe, 0Era, 365W) 206: [P] Drug Induced Acute pancreatitis (7Pe, 365W) 207: [P] Acquired Pure Red Cell Aplasia 208: [P] Neutropenic Fever (3Pe, 30Era) 209: [P] Hemolytic Anemia, Extra corpuscular Acquired - G6PD deficiency excluded (7Pe, 0Era, 365W) 210: [P] Hemolytic Anemia, Extra corpuscular Acquired (7Pe, 0Era, 365W) 211: [P] Pancytopenia, Acquired 213: [P] Acquired Neutropenia or unspecified leukopenia (21Pe, 365Era) 214: [P] Acquired Isolated Neutropenia or unspecified leukopenia (21Pe, 365Era) 215: [P] Isolated Immune Thrombocytopenia (180Pe, 365Era) 216: [P] Isolated Immune Thrombocytopenia in absence of common thrombocytopenia causes (180Pe, 365Era) 217: [P] Thrombotic microangiopathy or Microangiopathic hemolytic anemia 218: [P] Rhabdomyolysis (3Pe, 0Era, 180W) 219: [P] Sudden Cardiac arrest or cardiac death 220: [P] Angioedema (3Pe, 0Era, 180W) 221: [P] Anaphylaxis Non Environmental exposure related (1Pe, 0Era, 180W) 222: [P] Stevens-Johnson syndrome, toxic epidermal necrolysis spectrum 223: [P] Posterior reversible encephalopathy syndrome (PRES) 224: [P] Long QT Syndrome or QT prolonged (Acquired) 225: [P] Drug-induced Lupus (7Pe, 0Era, 365W) 226: [P] Drug Rash with Eosinophilia and Systemic Symptoms DRESS (1Pe, 0Era, 365W) 227: [P] Severe Cutaneous Adverse Reaction SCAR (SJS+TEN+DRESS+EM) (3Pe, 0Era, 365W) 228: [P] Severe Cutaneous Adverse Reaction SCAR (SJS+TEN+DRESS) (3Pe, 0Era, 365W) 229: [P] Progressive multifocal leukoencephalopathy 230: [P] Autoimmune hepatitis (1Pe, 0Era, 365W) 231: [P] Erythema multiforme (3Pe, 0Era, 365W) 232: [P] Paresthesia (3Pe, 0Era, 365W) 233: [P] Hemorrhagic stroke (1Pe, 0Era, 180W) 234: [P] Appendicitis (1Pe, 0Era, 365W) 235: [P] Guillain Barre syndrome (1Pe, 0Era, 365W) 236: [P] Idiopathic Peripheral Neuropathy (1Pe, 0Era, 365W) 237: [P] Kawasaki disease (1Pe, 0Era, 365W) 238: [P] Optic Neuritis (7Pe, 0Era, 365W) 239: [P] Narcolepsy events (1Pe, 0Era, 365W) 240: [P] Muscle weakness or monoplegia (1Pe, 0Era, 365W) 241: [P] Urticaria (1Pe, 0Era, 365W) 243: [P] Tinnitus (1Pe, 0Era, 365W) 244: [P] Dizziness (1Pe, 0Era, 365W) 245: [P] Hepatic Thrombosis (1Pe, 0Era, 365W) 246: [P] Portal vein thrombosis (1Pe, 0Era, 365W) 247: [P] Deep Vein Thrombosis DVT (1Pe, 0Era, 365W) 248: [P] Disseminated intravascular coagulation DIC (1Pe, 0Era, 365W) 249: [P] Ischemic (Non-hemorrhagic) Stroke (1Pe, 0Era, 365W) Deprecated Cohorts: No new cohorts were added in this release. Modified Cohorts: No cohorts were modified in this release.
New Cohorts: No new cohorts were added in this release.
Modified Cohorts: 85 were modified. These are only name modifications. These cohorts have not undergone Peer review process. They are not considered accepted. However, because of grandfathered status (i.e. these cohorts existed in Phenotype Library prior to version 3.0, results for these cohorts are computed as part of PhenotypeLibraryDiagnostics study package - unless withdrawn). The Cohort JSON specifications were not changed.
2: [P] COVID-19 diagnosis or SARS-CoV-2 test (1pos) (3Ps, 7Era)
3: [P] Cough (3Ps, 30Era)
4: [P] Diarrhea (7Ps, 30Era)
5: [P] Dyspnea (14Pe, 30Era)
6: [P] Fever (3Pe, 30Era)
7: [P]Headache, Migraine, Neurologic pain (7Pe, 30Era)
8: [P] Anosmia OR Hyposmia OR Dysgeusia (7Ps, 180Era)
9: [P] Sore throat (7Pe, 30Era)
10: [P] Nausea or Vomiting (3Pe, 30Era)
11: [P] Malaise or fatigue (3P, 30Era)
12: [P] Rhinitis or common cold (7P, 30Era)
13: [P] Myalgia (not including secondary causes) (3Pe, 30Era)
14: [P] Myalgia (3Pe, 30Era)
15: [P] Exposure to Viral Disease (7Pe, 30Era)
16: [P] Exposure to SARS-Cov 2 and coronavirus (7Pe, 30Era)
17: [P] Exposure to SARS-Cov 2 (7Pe, 30Era)
18: [P] Multiple Inflammatory Syndrome (30Pe, 30Era)
19: [P] Pneumonia (14Pe, 30Era)
20: [P] Bronchitis (14Pe, 90Era)
21: [P] Acute respiratory distress syndrome (ARDS) or Acute Respiratory Failure (3Pe, 30Era)
22: [P] SARS-CoV-2 testing (1Ps, 0Era)
23: [P] Hospitalization (1Pe, 30Era)
24: [P] Emergency room visits (0Pe, 0Era)
25: [P] All cause mortality
26: [P] Asthma or Chronic obstructive pulmonary disease (COPD) (FP)
27: [P] Asthma without COPD (FP)
28: [P] Chronic obstructive pulmonary disease (COPD) without asthma (FP)
30: [P] Tuberculosis (FP)
31: [P] Malignant neoplasm excluding non-melanoma skin cancer (FP)
32: [P] Obesity (FP)
33: [P] Dementia (FP)
34: [P] Hypertension (FP)
36: [P] Human immunodeficiency virus infection (FP)
37: [P] Hepatitis C (FP)
38: [P] Heart disease (FP)
40: [P] Diabetes Mellitus Type 2 (FP)
43: [P] Tuberculosis broad (FP)
45: [P] COVID-19 diagnosis with SARS-Cov-2 test (-3d to 3d) (3Pe, 21Era)
46: [P] COVID-19 diagnosis and SARS-CoV-2 test (1pos) within 3d (3Pe, 21Era)
47: [P] COVID-19 diagnosis and SARS-CoV-2 test (1pos) (0neg) within 3d (3Pe, 21Era)
48: [P] COVID-19 diagnosis and SARS-CoV-2 test (0pos upto 3d, 1neg within 3d) (3Pe, 7Era)
51: [P] SARS-CoV-2 test positive result (0Ps, 0Era)
52: [P] SARS-CoV-2 test negative result (0Ps, 0Era)
53: [P] SARS-CoV-2 test positive or negative result - keep persons with positive (0Ps, 0Era)
54: [P] Febrile seizure (1Ps, 0Era)
55: [P] COVID-19 diagnosis or SARS-CoV-2 test (1pos) (3Ps, 21Era)
56: [P] SARS-CoV-2 test (1pos) or COVID-19 diagnosis with (0 neg -3d to 3d) (3Ps, 21Era)
57: [P] Bleeding (1Ps, 30Era)
58: [P] SARS-CoV-2 test positive result (3Ps, 21Era)
59: [P] COVID-19 diagnosis with no SARS-CoV-2 test (3Ps, 21Era)
60: [P] SARS-CoV-2 test positive and negative result (0Ps, 0Era)
61: [P] Bradycardia or heart block with inpatient admission (1Pe, 30Era)
62: [P] Generalized Seizure (1Ps, 0Era)
63: [P] Transverse myelitis (or symptoms with transverse myelitis) 365dWO (1Ps, 0Era)
64: [P] Flu-like symptoms (3P, 30Era)
65: [P] Acute pancreatitis with inpatient admission (3Pe, 30Era)
66: [P] Acute renal failure with inpatient admission (3Pe, 30Era)
67: [P] Hepatic failure with inpatient admission (3Pe, 30Era)
68: [P] Heart failure with inpatient admission (3Pe, 30Era)
69: [P] Angioedema with inpatient admission (7Ps, 30Era)
70: [P] Stroke (ischemic or hemorrhagic) with inpatient admission (7Ps, 30Era)
71: [P] Acute myocardial infarction with inpatient admission (7Ps, 180Era)
72: [P] Influenza (narrow) (7Pe, 90Era)
74: [P] Hemorrhagic stroke (intracerebral bleeding) with inpatient admission (7Ps, 180Era)
75: [P] Ischemic stroke with inpatient admission (7Ps, 180Era)
76: [P] Transient ischemic attack with inpatient admission (7Ps, 30Era)
77: [P] Gastrointestinal bleeding with inpatient admission (7Ps, 30Era)
78: [P] Cardiac arrhythmia with inpatient admission (1Pe, 30Era)
79: [P] Dialysis with inpatient admission (1Ps, 7Era)
80: [P] Extracorporeal Membrane Oxygenation with inpatient admission (1Ps, 30Era)
81: [P] Cesarean section (7Pe, 180Era)
82: [P] Intensive services during hospitalization (1Ps, 30Era)
84: [P] SARS-CoV-2 test (1pos) or COVID-19 diagnosis with (1pos or 0 neg 0d to 3d) (3Ps, 180Era)
85: [P] SARS-CoV-2 test (1pos) or COVID-19 diagnosis with (1pos or 0 neg 0d to 3d) (3Ps, 21Era)
86: [P] SARS-CoV-2 test positive or negative result (0Ps, 0Era)
87: [P] SARS-CoV-2 test (1Ps, 0Era)
95: [P] Delirium (FP)
189: [P] Right Upper Quadrant Pain (Pe1, 3Era)
190: [P] Abdominal Distension (Pe1, 7Era)
191: [P] Fatigue, Malaise, Lethargy, Anorexia (Pe1, 1Era)
192: [P] Nausea or Vomiting (Pe1, 7Era)
193: [P] Jaundice or Itching (Pe1, 7Era)
194: [P] Encephalopathy or its presentations (Pe1, 7Era)
195: [P] Urothelial bladder cancer (FP)
197: [P] Coronary Artery Disease from vessel disease to ischemic injury (FP)
Withdrawn Cohorts: 13 were withdrawn prior to peer review. These cohorts have not undergone Peer review process. They are not considered accepted. It has been withdrawn prior to peer review. The Cohort JSON specifications were not changed. 29: [W] Autoimmune condition (FP) 35: [W] Chronic kidney disease (FP) 39: [W] End stage renal disease (FP) 41: [W] Chronic kidney disease broad (FP) 42: [W] End stage renal disease broad (FP) 44: [W] COVID-19 diagnosis (3Pe, 7Era) 73: [W] Pregnancy (270P, 0Era) 123: [W] First event of Suicide attempt, including injuries and poisonings with undetermined, 365 days 196: [W] Rheumatoid arthritis (FP) 198: [W] Crohns disease (FP) 199: [W] Major Depressive Disorder (FP) 200: [W] Plaque psoriasis (FP) 201: [W] Ulcerative colitis (FP)
Vignette: Created new vignette 'Guidelines on writing clinical description for Condition Phenotypes' by taking content out of 'Cohort Definition Submission Requirements'. Added several vignette stubs with cross reference.
Vignette updates
Vignette: Table format for Cohort Definitions in OHDSI Phenotype Library using reactable.
Added Vignette: Cohort Definition Submission Requirements.
Added Vignette: Cohort Definitions in OHDSI Phenotype Library Added new function: to get log of phenotype changes
Added Vignette: How to use Phenotype Library R Package Added tests to conform to HADES This package is now part of OHDSI HADES.
Cohorts in this release are all new. Source: atlas-phenotype.ohdsi.org
Initial version using new structure.